Yeah I know, but they had to do it in order to get funding for their operations. Of course, this came at the expense of previous holders. At least now the company should be worth more, and could put something of value to the investors.
We could see a rise in the coming months, as they should be laying off with their share sales.
Also this generally happens on Bio-Tech stocks, they usually always do a secondary offering after a phase II or something, and I wasn't surprised they did a public offering here.
This could play out like SLTD, after they uplisted and sold shares in an offering (which also destroyed their share price). It dropped all the way down to around $2.50 (from a offering priced at I think $4.50 per share) before bouncing back.
Nothing to see here. ~CEO